Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML.

Leukemia - 1 Jun 2017

Kats L M, Vervoort S J, Cole R, Rogers A J, Gregory G P, Vidacs E, Li J, Nagaraja R, Yen K E, Johnstone R W

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Antineoplastic Agents
Share to Enzyme Inhibitors
Share to Isocitrate Dehydrogenase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Pharmacogenetics

Share to Triazines

Source

Identifiers

PMID: 28280273
DOI: 10.1038/leu.2017.84

Genes

IDH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML.PMID 28280273Read ↗

Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models.Semantic proximity Read ↗

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia.Semantic proximity Read ↗

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.Semantic proximity Read ↗

T cells take aim in AML: targeting IDH2.Semantic proximity Read ↗

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.Semantic proximity Read ↗

Hitting the target in IDH2 mutant AML.Semantic proximity Read ↗

Stein EM. IDH2 inhibition in AML. Blood. 2023;141(2):124-125.Semantic proximity Read ↗

The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.Semantic proximity Read ↗

Targeting IDH: the next big thing in AML.Semantic proximity Read ↗

AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in VivoSemantic proximity Read ↗

IDH1/IDH2 Inhibition in Acute Myeloid LeukemiaSemantic proximity Read ↗

Recent advances of IDH1 mutant inhibitor in cancer therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.